Tokyo Tape
Sign in
← M3

Quarterly report · Q1

2413.TEDINET S100RK8S
Period2023-04-01 → 2023-06-30
Filed2023-08-10
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥57.4bn2023-04-01 → 2023-06-30Cons.Revenue IFRS
Revenue¥230.8bn2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥57.0bn2022-04-01 → 2022-06-30Cons.Revenue IFRS
Operating income¥18.0bn2023-04-01 → 2023-06-30Cons.Operating profit loss IFRS
Operating income¥18.7bn2022-04-01 → 2022-06-30Cons.Operating profit loss IFRS
Profit before tax¥19.8bn2023-04-01 → 2023-06-30Cons.Profit loss before tax IFRS
Profit before tax¥74.3bn2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥19.7bn2022-04-01 → 2022-06-30Cons.Profit loss before tax IFRS
Net income (owners)¥12.4bn2023-04-01 → 2023-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥49.0bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥12.1bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income¥13.6bn2023-04-01 → 2023-06-30Cons.Profit loss IFRS
Net income¥13.5bn2022-04-01 → 2022-06-30Cons.Profit loss IFRS
Total assets¥439.6bnat 2023-06-30Cons.Assets IFRS
Total assets¥400.6bnat 2023-03-31Cons.Assets IFRS
Total assets¥357.5bnat 2022-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥110.9bnat 2023-06-30Cons.Liabilities IFRS
Total liabilities¥91.1bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥328.8bnat 2023-06-30Cons.Equity IFRS
Net assets / equity¥309.5bnat 2023-03-31Cons.Equity IFRS
Net assets / equity¥275.1bnat 2022-06-30Cons.Equity IFRS
Net assets / equity¥264.0bnat 2022-03-31dCons.Equity IFRS
Equity (owners)¥316.8bnat 2023-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥302.6bnat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥268.8bnat 2022-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥130.7bnat 2023-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥118.3bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥88.8bnat 2022-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥104.3bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥12.0bn2023-04-01 → 2023-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥57.1bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥9.4bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥18.2bn2023-04-01 → 2023-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥21.9bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥14.7bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥16.4bn2023-04-01 → 2023-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥22.8bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥12.5bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥18.292023-04-01 → 2023-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥72.222022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥17.862022-04-01 → 2022-06-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥18.272023-04-01 → 2023-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥72.172022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥17.852022-04-01 → 2022-06-30Cons.Diluted earnings loss per share IFRS
Equity ratio72.1%at 2023-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio75.5%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio75.2%at 2022-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-06-30−¥1.0bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-06-30−¥1.0bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-06-30¥167m
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue2023-04-01 → 2023-06-30¥5.6bn
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue external2023-04-01 → 2023-06-30¥5.6bn
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥16m
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentsegment profit2023-04-01 → 2023-06-30¥2.7bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue2023-04-01 → 2023-06-30¥7.0bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue external2023-04-01 → 2023-06-30¥6.8bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥114m
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentsegment profit2023-04-01 → 2023-06-30¥1.9bn
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue2023-04-01 → 2023-06-30¥21.9bn
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue external2023-04-01 → 2023-06-30¥21.1bn
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥868m
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentsegment profit2023-04-01 → 2023-06-30¥8.9bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue2023-04-01 → 2023-06-30¥15.7bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue external2023-04-01 → 2023-06-30¥15.7bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥11m
jpcrp040300-q1r_E05425-000Overseasreportable segmentsegment profit2023-04-01 → 2023-06-30¥3.7bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentrevenue2023-04-01 → 2023-06-30¥7.7bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentrevenue external2023-04-01 → 2023-06-30¥7.7bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥3m
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentsegment profit2023-04-01 → 2023-06-30¥831m
—segment totalrevenue2023-04-01 → 2023-06-30¥57.9bn
—segment totalrevenue external2023-04-01 → 2023-06-30¥56.9bn
—segment totalrevenue intersegment2023-04-01 → 2023-06-30¥1.0bn
—segment totalsegment profit2023-04-01 → 2023-06-30¥18.0bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥1.7bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥1.7bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥471m
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue2022-04-01 → 2022-06-30¥5.5bn
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue external2022-04-01 → 2022-06-30¥5.2bn
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥267m
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentsegment profit2022-04-01 → 2022-06-30¥2.8bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue2022-04-01 → 2022-06-30¥7.2bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue external2022-04-01 → 2022-06-30¥7.0bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥162m
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentsegment profit2022-04-01 → 2022-06-30¥2.2bn
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue2022-04-01 → 2022-06-30¥20.2bn
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue external2022-04-01 → 2022-06-30¥19.3bn
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥951m
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentsegment profit2022-04-01 → 2022-06-30¥8.8bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue2022-04-01 → 2022-06-30¥14.9bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue external2022-04-01 → 2022-06-30¥14.9bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥2m
jpcrp040300-q1r_E05425-000Overseasreportable segmentsegment profit2022-04-01 → 2022-06-30¥4.0bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentrevenue2022-04-01 → 2022-06-30¥10.2bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentrevenue external2022-04-01 → 2022-06-30¥9.9bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥304m
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentsegment profit2022-04-01 → 2022-06-30¥1.4bn
—segment totalrevenue2022-04-01 → 2022-06-30¥58.0bn
—segment totalrevenue external2022-04-01 → 2022-06-30¥56.3bn
—segment totalrevenue intersegment2022-04-01 → 2022-06-30¥1.7bn
—segment totalsegment profit2022-04-01 → 2022-06-30¥19.3bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 587
ItemContextValueUnit
Cash and cash equivalents IFRSPrior1QuarterInstant88751000000JPY
Cash and cash equivalents IFRSCurrentQuarterInstant130739000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000MedicalPlatformReportableSegmentMember19273000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000EvidenceSolutionReportableSegmentMember7012000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000CareerSolutionReportableSegmentMember5198000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000SiteSolutionReportableSegmentMember9916000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000OverseasReportableSegmentMember14919000000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReportableSegmentsMember56317000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000OtherEmergingBusinessMember678000000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSPrior1YTDDuration56996000000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000MedicalPlatformReportableSegmentMember951000000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000EvidenceSolutionReportableSegmentMember162000000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000CareerSolutionReportableSegmentMember267000000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000SiteSolutionReportableSegmentMember304000000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000OverseasReportableSegmentMember2000000JPY
Intersegment revenue IFRSPrior1YTDDuration_ReportableSegmentsMember1685000000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000OtherEmergingBusinessMember23000000JPY
Intersegment revenue IFRSPrior1YTDDuration_ReconcilingItemsMember-1709000000JPY
Intersegment revenue IFRSPrior1YTDDuration－JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000MedicalPlatformReportableSegmentMember20223000000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000EvidenceSolutionReportableSegmentMember7174000000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000CareerSolutionReportableSegmentMember5464000000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000SiteSolutionReportableSegmentMember10220000000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000OverseasReportableSegmentMember14921000000JPY
Revenue IFRSPrior1YTDDuration_ReportableSegmentsMember58003000000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000OtherEmergingBusinessMember702000000JPY
Revenue IFRSPrior1YTDDuration_ReconcilingItemsMember-1709000000JPY
Revenue IFRSPrior1YTDDuration56996000000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000MedicalPlatformReportableSegmentMember8786000000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000EvidenceSolutionReportableSegmentMember2235000000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000CareerSolutionReportableSegmentMember2830000000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000SiteSolutionReportableSegmentMember1448000000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000OverseasReportableSegmentMember4040000000JPY
Operating profit loss IFRSPrior1YTDDuration_ReportableSegmentsMember19339000000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000OtherEmergingBusinessMember-173000000JPY
Operating profit loss IFRSPrior1YTDDuration_ReconcilingItemsMember-471000000JPY
Operating profit loss IFRSPrior1YTDDuration18695000000JPY
Finance income and expenses net IFRSPrior1YTDDuration1053000000JPY
Profit loss before tax IFRSPrior1YTDDuration19748000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000MedicalPlatformReportableSegmentMember659000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000EvidenceSolutionReportableSegmentMember131000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000CareerSolutionReportableSegmentMember24000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000SiteSolutionReportableSegmentMember270000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000OverseasReportableSegmentMember551000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_ReportableSegmentsMember1635000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000OtherEmergingBusinessMember55000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration1691000000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q1r_E05425-000MedicalPlatformReportableSegmentMember21079000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-06-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass